Comparative insilico studies on domain prediction of rheumatoid factors in rheumatoid arthritis and sjogren’s syndrome

Background: Autoimmune disorders are affect our own body cells by destroying organs, tissues and cells, yet the reason is unknown. Since the causative factor for autoimmune disoreder is questionable. The numerous autoimmune disoreders are available, all those are associated with one another by sharing symptoms, diagnosis and treatment. The affected body part also more or less similar. Among these, Rheumatoid arthritis and sjogrens syndrome receives more attention and turns the whole physician’s concentrations to that side. Because the peoples those who have affected by RA are more susceptible to SS and vice versa. The principle behind that the common agent RF is involved in both diseases. In addition to this antiSSA and antiSSB are mostly involved in sjogren’s syndrome. Aim: To predict the common domains of rheumatoid factors (both rheumatoid arthritis and sjogren’s syndrome) and antiSSA, antiSSB using computational tools. Methods: Domains have been predicted for each factor using insilico tools and the sequence positions are displayed with the respective E-value. Results: From these predictions, we have concluded that IGv domain of rheumatoid factor is majorly involved in both rheumatoid arthritis and Sjogren’s syndrome. The prediction of antiSSA and antiSSB shows that vWFA, TROVE, and SPRY are the common domains involved only in sjogren’s syndrome. But IGv, IGc1, and IG are the common domains mainly present in rheumatoid arthritis as well as Sjogren’s syndrome. Conclusions: The people’s those who suffered by rheumatoid arthiritis having more number of chances to get sjogren’s symdrome too. Because the domain IGv is commonly present in the rheumatoid factor of rheumatoid arthiritis and sjogren’s syndrome. Future Directions: By predicting this domain we can detect the malfunction or mutation, and onset of disease occurs, and model them as potential drug targets and propose the development of a common drug to tackle the disorder.